EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies

Tao Liu, Prescott G Woodruff, Xiaobo Zhou

European Respiratory Journal · 2024-08 · 64 (2) · 2300826

DOI: 10.1183/13993003.00826-2023 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Respiratory Journal, online erschienen am 02.05.2024. Verfasst von Tao Liu und 2 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Provincial Key Laboratory of Critical Care Medicine and Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast…. Hauptthemen laut MEDLINE: Asthma, Anti-Asthmatic Agents. Die Arbeit wurde bisher 91-mal zitiert (Crossref) und nennt 215 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Asthma is a prevalent pulmonary disease that affects more than 300 million people worldwide and imposes a substantial economic burden. While medication can effectively control symptoms in some patients, severe asthma attacks, driven by airway inflammation induced by environmental and infectious exposures, continue to be a major cause of asthma-related mortality. Heterogeneous phenotypes of asthma include type 2 (T2) and non-T2 asthma. Non-T2 asthma is often observed in patients with severe and/or steroid-resistant asthma. This review covers the molecular mechanisms, clinical phenotypes, causes and promising treatments of non-T2 severe asthma. Specifically, we discuss the signalling pathways for non-T2 asthma including the activation of inflammasomes, interferon responses and interleukin-17 pathways, and their contributions to the subtypes, progression and severity of non-T2 asthma. Understanding the molecular mechanisms and genetic determinants underlying non-T2 asthma could form the basis for precision medicine in severe asthma treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAnti-Asthmatic AgentsHumansPhenotypeSignal TransductionSeverity of Illness IndexInterleukin-17InflammasomesInterferonsInflammation

Substanzen

Anti-Asthmatic AgentsInterleukin-17InflammasomesInterferons

Autor:innen und Institutionen

  • Jiangsu Provincial Key Laboratory of Critical Care Medicine and Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
  • Department of Biochemistry and Molecular Biology, School of Medicine, Southeast University, Nanjing, China.
  • Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
  • Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine and Cardiovascular Research Institute, University of California San Francisco, San Francisco, CA, USA.
  • Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA xiaobo.zhou@channing.harvard.edu.

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Liu, T., Woodruff, P. G., & Zhou, X. (2024). Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. European Respiratory Journal, 64(2), 2300826. https://doi.org/10.1183/13993003.00826-2023

Vancouver

Liu T, Woodruff PG, Zhou X. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. European Respiratory Journal. 2024;64(2):2300826. doi:10.1183/13993003.00826-2023

BibTeX
@article{Liu2024,
  author = {Liu, Tao and Woodruff, Prescott G and Zhou, Xiaobo},
  title = {Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies},
  journal = {European Respiratory Journal},
  year = {2024},
  volume = {64},
  number = {2},
  pages = {2300826},
  doi = {10.1183/13993003.00826-2023}
}
Kostenlos starten →